The Efficacy of DMARDs in Patients with Rheumatoid Arthritis.

概要

論文の詳細を見る
The efficacy of disease modifying anti-rheumatic drugs (DMARDs) was studied retrospectively in patients with rheumatoid arthritis. Duration and continuance of medication was evaluated using the survival rate method (Kaplan-Meier) in four drug groups: Auranof in group (AF, N=52), Aurothiomalate Sodium group (GST, N=34), Bucillamine group (BUC, N=53), and the Methotrexate group (MTX, N=27).Sixty percent of patients in AF were found to still be taking the medication at 12 months, 50%, and 35%, at 24 and 36 months, respectively. Those in GST were 94%, 83%, and 79%, in BUC 79%, 60%, and 45%, and in MTX 75%, 55%, and 35% at 12, 24, and 36 months, respectively. We concluded Aurothiomalate Sodium is the most effective drug among these four drugs for the treatment of rheumatoid arthritis.
西日本整形・災害外科学会の論文